



**JDRF's mission is to find a cure for diabetes and its complications through the support of research. JDRF is also committed to developing new and better treatments to improve the lives of people with type 1 diabetes in the near term and keep them healthy while we advance toward a cure.**

- Since its founding in 1970 by parents of children with type 1 diabetes, internationally JDRF has funded more than \$1.4 billion (U.S.) in research. In FY2009 alone, JDRFI funded nearly \$101 million (U.S.), more than \$42 million (U.S.) of which represented new scientific projects.
- Eighty cents of every dollar JDRF expends goes to support research and research-related education.
- In FY2009, JDRFI funded research projects in 22 countries, including more than 40 human clinical trials.

## JDRF's Research Goals

JDRF is committed to aggressively following the most promising paths to **cure**, better **treat**, and **prevent** type 1 diabetes. We are targeting our resources on science that seeks to:

- Arrest the immune attack on the insulin-producing beta cells
- Restore or replace beta cell function
- Better control blood sugar levels
- Protect people from – or reverse – complications

## FY2009 JDRFI Research Funding

Immune Therapies	\$33 million (U.S.)
Beta Cell Therapies	\$39.8 million (U.S.)
Glucose Control	\$5.9 million (U.S.)
Complications Therapies	\$22.1 million (U.S.)
<b>Total</b>	<b>\$100.8 million (U.S.)</b>

## Therapeutic Areas

*JDRF targets its research funding in four "Therapeutic Areas:"*

### Immune Therapies

This area focuses on ways to stop the immune system attack on the body's insulin-producing beta cells that causes type 1 diabetes. Within this area, JDRF is prioritizing antigen-specific therapies that would reverse the immune attack in type 1 diabetes without suppressing the entire immune system.

### Beta Cell Therapies

This area aims to find ways to restore the body's ability to make insulin through the:

- Regeneration of insulin-producing beta cells (i.e. triggering the body to re-grow beta cells) and;
- Replacement of the beta cells lost to diabetes.

JDRF is prioritizing regeneration because of its potential to restore beta cell function in the largest number of people living with type 1 diabetes.

### Glucose Control

This area seeks to identify ways to dramatically improve blood glucose control while avoiding dangerous highs and lows in people at all stages of type 1 diabetes. JDRF is prioritizing the development of a closed loop artificial pancreas, a device combining glucose monitors and insulin pumps, to enable people to achieve tight blood sugar control and reduce their risk of complications. JDRF is also prioritizing the development of novel insulins that are glucose-responsive, faster-acting, easier to use, and more effective.

### Complications Therapies

This area focuses on ways to free people from the devastating long-term complications that can accompany diabetes, including diseases of the eyes, nerves, and kidneys. JDRF is prioritizing research in complications protection, or new approaches to assess risk and block complications from developing and progressing.